AYTU BIOPHARMA, INC Interest Expense Nonoperating
AYTU BIOPHARMA, INC (AYTU) reported Interest Expense Nonoperating of $1.90 million for the 12-month period ending 2026-06-30, per its 10-K filed 2026-09-22.
Financial Statements › Expense Statement
us-gaap:InterestExpenseNonoperating · last filed 2026-09-22
- AYTU BIOPHARMA, INC interest expense nonoperating for the quarter ending 2026-06-30 was $383.00K, a 47.53% decline year-over-year.
- AYTU BIOPHARMA, INC interest expense nonoperating for the quarter ending 2026-03-31 was $436.00K, a 51.56% decline year-over-year.
- AYTU BIOPHARMA, INC interest expense nonoperating for the quarter ending 2025-12-31 was $560.00K, a 48.10% decline year-over-year.
- AYTU BIOPHARMA, INC interest expense nonoperating for the quarter ending 2025-09-30 was $516.00K, a 48.09% decline year-over-year.
- AYTU BIOPHARMA, INC interest expense nonoperating for fiscal 2026 was $1.90M, a 48.83% decline from fiscal 2025.
- AYTU BIOPHARMA, INC interest expense nonoperating for fiscal 2025 was $3.70M, a 26.80% decline from fiscal 2024.
- AYTU BIOPHARMA, INC interest expense nonoperating for fiscal 2024 was $5.06M, a 1.93% increase from fiscal 2023.
- AYTU BIOPHARMA, INC interest expense nonoperating for fiscal 2023 was $4.96M.
| Period end | Interest Expense Nonoperating 3 month | Interest Expense Nonoperating 6 month | Interest Expense Nonoperating 9 month | Interest Expense Nonoperating 12 month | Interest Expense Nonoperating 12 month as first filed |
|---|---|---|---|---|---|
| 2026-06-30 | $383.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-09-22 | $819.00K derived: sum of 2 quarters · filed 2026-09-22 | $1.38M derived: sum of 3 quarters · filed 2026-09-22 | $1.90M 10-K · filed 2026-09-22 | |
| 2026-03-31 | $436.00K 10-Q · filed 2026-05-13 | $996.00K derived: sum of 2 quarters · filed 2026-05-13 | $1.51M 10-Q · filed 2026-05-13 | $2.24M derived: sum of 4 quarters · filed 2026-09-22 | |
| 2025-12-31 | $560.00K 10-Q · filed 2026-02-03 | $1.08M 10-Q · filed 2026-02-03 | $1.81M derived: sum of 3 quarters · filed 2026-09-22 | $2.71M derived: sum of 4 quarters · filed 2026-09-22 | |
| 2025-09-30 | $516.00K 10-Q · filed 2025-11-13 | $1.25M derived: sum of 2 quarters · filed 2026-09-22 | $2.15M derived: sum of 3 quarters · filed 2026-09-22 | $3.23M derived: sum of 4 quarters · filed 2026-09-22 | |
| 2025-06-30 | $730.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-09-22 | $1.63M derived: sum of 2 quarters · filed 2026-09-22 | $2.71M derived: sum of 3 quarters · filed 2026-09-22 | $3.70M 10-K · filed 2026-09-22 | |
| 2025-03-31 | $900.00K 10-Q · filed 2026-05-13 | $1.98M derived: sum of 2 quarters · filed 2026-05-13 | $2.97M 10-Q · filed 2026-05-13 | $4.23M derived: sum of 4 quarters · filed 2026-05-13 | |
| 2024-12-31 | $1.08M 10-Q · filed 2026-02-03 | $2.07M 10-Q · filed 2026-02-03 | $3.33M derived: sum of 3 quarters · filed 2026-02-03 | $4.58M derived: sum of 4 quarters · filed 2026-02-03 | |
| 2024-09-30 | $994.00K 10-Q · filed 2025-11-13 | $2.25M derived: sum of 2 quarters · filed 2025-11-13 | $3.50M derived: sum of 3 quarters · filed 2025-11-13 | $4.77M derived: sum of 4 quarters · filed 2025-11-13 | |
| 2024-06-30 | $1.25M derived: 10-K 12 month − 10-Q 9 month · filed 2025-09-23 | $2.51M derived: sum of 2 quarters · filed 2025-09-23 | $3.78M derived: sum of 3 quarters · filed 2025-09-23 | $5.06M 10-K · filed 2025-09-23 | $4.79M 10-K · filed 2024-09-26 |
| 2024-03-31 | $1.26M 10-Q · filed 2025-05-14 | $2.52M derived: sum of 2 quarters · filed 2025-05-14 | $3.81M 10-Q · filed 2025-05-14 | ||
| 2023-12-31 | $1.27M 10-Q · filed 2025-02-12 | $2.55M 10-Q · filed 2025-02-12 | |||
| 2023-09-30 | $1.28M 10-Q · filed 2024-11-13 | ||||
| 2023-06-30 | $4.96M 10-K · filed 2024-09-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NextCure, Inc. (NXTC) | United States | $0.024B | -0.15 |
| TherapeuticsMD, Inc. (TXMD) | United States | $0.024B | -117.87 |
| ARTELO BIOSCIENCES, INC. (ARTL) | United States | $0.023B | |
| KYNTRA BIO, INC. (KYNB) | United States | $0.028B | 0.17 |
| Transcode Therapeutics, Inc. (RNAZ) | United States | $0.029B | -0.12 |
| Cocrystal Pharma, Inc. (COCP) | United States | $0.022B | |
| Hepion Pharmaceuticals, Inc. (HEPA) | United States | $0.029B | -0.62 |
| ATOSSA THERAPEUTICS, INC. (ATOS) | United States | $0.021B | -0.52 |
| IGC Pharma, Inc. (IGC) | United States | $0.029B | -5.98 |
| Neuphoria Therapeutics Inc. (NEUP) | United States | $0.020B | -1.77 |